United States· US:0310-0075_c54223d3-f3c7-4186-afa0-429d84805826
ETCAMAH
A camizestrant product containing camizestrant, registered in United States by AstraZeneca Pharmaceuticals LP. The same ATC class is registered in 6 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Camizestrant is registered in 6 of 19 countries.
Countries holding a registration under ATC L02BA05 (camizestrant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Camizestrant · ATC L02BA05
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CAMIZESTRANT
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Country
- United States (US)
- ATC code
- L02BA05
- ATC class
- Camizestrant
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110310-0075-01
- ndc110310-0075-95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Camizestrant in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEtcamah 75 mgAstraZeneca
- CzechiaETCAMAHAstraZeneca AB, Södertälje
- FinlandETCAMAHAstraZeneca AB
- PolandEtcamahAstraZeneca AB
- SwedenEtcamah 75 mg Filmdragerad tablettAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Etcamah
- Liechtenstein · Etcamah
- Norway · Etcamah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8bdb409e-ca08-4dbb-ba23-747c3b843300 GET /v1/drugs/8bdb409e-ca08-4dbb-ba23-747c3b843300?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "75",
"substance": "CAMIZESTRANT",
"productndc": "0310-0075",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA220359",
"marketing_category": "NDA"
}See everything about camizestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.